Vertex Pharmaceuticals Inc. closed 18.83% below its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that Vertex Pharmaceuticals, Novo Nordisk and Bristol Myers Squibb developed for ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

The hefty tariffs President-elect Trump has pledged to levy on U.S. imports could impact the price and availability of pharmaceutical drugs. Trump has floated 25 percent tariffs on imports from ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that doesn't change the fact that the returns over ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK, Dec 31 (Reuters) - Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer (PFE.N), opens new tab COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ ...